Shire: Senior Assistant Company Secretary

The following excerpt is from the company's SEC filing.

For further information please contact:

Investor Relations

Matthew Osborne

mattosborne@shire.com

+1 781 482 9502

Sarah Elton-Farr

seltonfarr@shire.com

+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic condi tions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever Shire plc makes a similar move, sign up!

Other recent filings from the company include the following:

Shire: Not For Release, Publication Or Distribution In Whole Or In Part In, Into Or From Any Jurisdiction Where To Do So Would Constitute A Violation Of The Relevant Laws Or Regulations Of That Jurisd - Sept. 19, 2018
Shire: Not For Release, Publication Or Distribution In Whole Or In Part In, Into Or From Any Jurisdiction Where To Do So Would Constitute A Violation Of The Relevant Laws Or Regulations Of That Jurisd - Sept. 13, 2018
Shire Announces The Pricing Terms And Increase In The Maximum Tender Amount Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes - Sept. 10, 2018
Shire Announces Early Results Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes - Sept. 10, 2018
Shire Completes Sale Of Oncology Franchise - Aug. 31, 2018

Auto Refresh

Feedback